Status:
COMPLETED
Maintenance Plasma Exchange for Neuromyelitis Optica
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Terumo BCT
Conditions:
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO ...
Detailed Description
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO ...
Eligibility Criteria
Inclusion
- Neuromyelitis optica
- Neuromyelitis optica spectrum disorder
- Recurrent idiopathic longitudinally extensive myelitis
- Age 18 years or greater
Exclusion
- Any condition that in the opinion of the investigator could increase a participant's risk by participating in the observational study or confound the outcome of the study
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 9 2015
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01500681
Start Date
June 1 2012
End Date
July 9 2015
Last Update
December 27 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States, 85259
2
Mayo Clinic
Rochester, Minnesota, United States, 55905